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INTRODUCTION
Glaucoma is a chronic disease that frequently requires long-term 
treatment with topical ocular hypotensive eyedrops. The use of an -
tiglaucoma medications has been associated with ocular surface 
di sease (OSD)(1,2), in part due to preservatives used in these medica-
tions(3). Benzalkonium chloride (BAK), the most commonly found pre-
servative in antiglaucoma medications, has been shown to decrease 
the stability of the precorneal tear film due to a detergent effect on 
the lipid layer and to a reduction in the density of goblet cells(4).
Some authors(2) applied the ocular surface disease index (OSDI), 
a validated questionnaire(5) to investigate symptoms secondary to 
ocular surface disease, to 101 patients with open-angle glaucoma 
or ocular hypertension and reported that 59% of patients had scores 
compatible with ocular surface disease in at least 1 eye. Furthermore, 
they evaluated the tear break-up time in these patients and observed 
that 78% had abnormal tear quality in at least one eye. Recently, other 
authors(1) in a prospective multicentered observational study, applied 
the OSDI questionnaire to 630 glaucoma patients and found that 
48.4% had scores indicative of mild (n=134, 21.3%), moderate (n=84, 
13.3%), or severe (n=87, 13.8%) symptoms of OSD. 
OSD may result in a myriad of ocular symptoms and signs, inclu-
ding burning/stinging, itching, foreign body sensation, tearing, and 
dry eye sensation(6,7). When examined, patients with OSD typically 
present with variable levels of abnormal fluorescein and lissamine 
green staining of the cornea and conjunctiva, reduced tear break-up 
time, and an abnormal Schirmer’s test(6,7). Baffa et al.(8) examined 21 
patients with glaucoma and 20 age-matched controls and found 
that fluorescein and lissamine green staining were significantly more 
intense, and the tear break-up time was significantly reduced in the 
glaucoma group. Furthermore, several authors have suggested that 
OSD has a negative impact on the patients’ quality of life(7,9). 
The initial approach to treat OSD relies on the use of artificial tears, 
although other options include omega-3 essential fatty acids, topi-
cal cyclosporine, anti-inflammatory agents, and lacrimal plugs(10-15). 
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ABSTRACT
Purpose: To evaluate the need for artificial tears by glaucoma patients under 
topical hypotensive treatment and to identify risk factors associated with it. 
Methods: The charts of 175 glaucoma patients under medical treatment and 175 
age-matched controls were reviewed. Age, gender, use of artificial tears, number 
of glaucoma medications used, and duration of treatment were recorded. 
Results: Significantly more glaucoma patients (n=92; 52.6%) used artificial tears 
compared to age-matched controls (n=31; 17.7%) (p<0.001). Significantly more 
females (n=81; 39%) than males (n=42; 28.9%) used artificial tears (p=0.036). When 
the whole population was analyzed, female gender (OR=1.63) and the presence 
of glaucoma (OR= 5.14) were risk factors for the use of artificial tears (p<0.05). 
When the glaucoma population was analyzed, female gender (OR=2.57), number 
of medications >2 (OR=1.92), and duration of treatment >5 years (OR=2.93) were 
risk factors for the use of artificial tears (p<0.05). 
Conclusions: Topical treatment with antiglaucoma medication is a risk factor for 
the use of artificial tears. Female gender and long-term treatment of glaucoma with 
two or more medications were aggravating factors for the need for artificial tears.
Keywords: Glaucoma; Ophthalmic solutions; Antihypertensive agents/therapeutic 
use; Comparative study; Risk factors
RESUMO
Objetivo: Avaliar a necessidade do uso de lágrimas artificiais por pacientes com 
glau coma recebendo tratamento medicamentoso e identificar fatores de risco asso­
ciados ao seu uso. 
Métodos: Os prontuários de 175 pacientes com glaucoma sob tratamento medica­
mentoso e de 175 controles pareados por idade foram revistos. Os seguintes dados 
foram registrados: idade, sexo, uso de lágrimas artificiais, número de medicações 
antiglaucomatosas e duração do tratamento do glaucoma. 
Resultados: Um número significativamente maior de pacientes com glaucoma (n=92; 
52,6%) usava lágrimas artificiais em relação ao grupo controle (n=31; 17,7%) (p<0,001). 
Um número significativamente maior de mulheres (n=81; 39%) usava lágrimas 
artificias em relação aos homens (n=42; 28,9%) (p=0,036). Quando a população foi 
analisada como um todo, sexo feminino (OR=1,63) e presença de glaucoma (OR=5,14) 
foram fatores de risco para o uso de lágrimas artificiais (p<0,05). Quando apenas a 
população de glaucomatosos foi analisada, número de medicações >2 (OR=1,92) 
e duração do tratamento >5 anos (OR=2,93) foram fatores de risco para o uso de 
lágrimas artificiais (p<0,05). 
Conclusões: O tratamento com colírios antiglaucomatosos é um fator de risco para 
o uso de lágrimas artificiais. Sexo feminino e tratamento a longo prazo com duas ou 
mais medicações são fatores de risco adicionais para o uso de lágrimas artificiais.
Descritores: Glaucoma; Soluções oftálmicas/uso terapêutico; Anti­hipertensivos/uso 
terapêutico; Estudo comparativo; Fatores de risco
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The purpose of this study is to evaluate the need for artificial tears 
among glaucoma patients under topical treatment, and to identify 
risk factors associated with it. We hypothesize that, since the use of 
antiglaucoma medication is associated with OSD, this may increase 
the necessity of artificial tears in these patients. 
METHODS
This was a retrospective, comparative study approved by the 
Ethics Committee/Investigational Review Board of the University of 
Campinas, Brazil. The charts of 175 consecutive glaucoma patients 
and 175 age-matched (+2 years) controls followed at two private offi-
ces (VPC and RA) were reviewed. Both Institutions followed patients 
with glaucoma and patients without glaucoma. 
The following characteristics were listed as inclusion criteria for 
the glaucoma group: diagnosis of glaucoma (primary open-angle, 
primary angle-closure, pigmentary glaucoma, or pseudoexfoliative 
glaucoma), and use of antiglaucoma medications. Patients included 
in the control group were followed for other ocular conditions, inclu-
ding refractive errors and cataract. Patients with previous intraocular 
surgery (i.e phacoemulsification, trabeculectomy, implant device, 
etc), previous laser surgery (except laser iridotomy), or use of contact 
lens were excluded from both groups. Patients previously diagnosed 
with dry eyes were not excluded from the study. 
The following data was retrieved from the charts of both groups: 
age, gender, use of systemic drugs associated with dry eye (anti-his-
taminics, antidepressants, anti-hypertensives, cholinergic agents), 
use of artificial tears, use of topical cyclosporine, and insertion of 
la crimal plug at the last examination. In the glaucoma group, we 
also evaluated the type of glaucoma, number and type of glaucoma 
medications, and duration of glaucoma treatment.
We compared the frequency of use of artificial tears in both 
po pulations using the Chi square or the Fisher exact test. We also 
investigated risk factors associated with the use of artificial tears in 
both groups and specifically in the glaucoma population applying 
the Cox-proportional hazard test. P values of less than 0.05 were 
considered statistically significant.
RESULTS
Table 1 lists the demographics of both populations. There were 
no significant differences regarding mean age, distribution of gender, 
or race between the groups (p>0.05). Most of the glaucoma patients 
had primary open-angle glaucoma (POAG) (82%), and used one an -
tiglaucoma topical medication (55%) (Table 2). Patients in the glau-
coma group had been treated for a mean of 4.4 + 4.6 years (range: 1 
month to 38 years). Prostaglandin analogues alone (46%) were used 
more frequently than other antiglaucoma medications. However, be -
tablockers were also used by a large group of patients either alone 
(23%) or in fixed combinations with other drugs (50%). 
Significantly more glaucoma patients (n=92; 52.6%) used artificial 
tears compared to age-matched controls (n=31; 17.7%) (p<0.001). 
Significantly more females (n=81; 39%) than males (n=42; 28.9%) 
used artificial tears (p=0.036). When glaucoma patients and controls 
were analyzed as a whole, female gender (OR=1.63) and glaucoma 
diagnosis (OR=5.15) were risk factors for the use of artificial tears 
(Table 3). 
When the glaucoma group was analyzed separately, female 
gender remained a significant risk factor for the use of artificial tears 
(OR=2.57), along with the use of 2 or more antiglaucoma medications 
(OR=1.92) and duration of treatment greater than 5 years (OR=2.92). 
We could not establish a relationship between type of antiglaucoma 
medication and the need for artificial tears (Table 4). 
DISCUSSION
Our findings confirm our hypothesis, i.e. that glaucoma patients 
present with a higher need for the use of more artificial tears than 
age-matched controls, which is in agreement with previous re-
ports(1,2,16). In a national panel survey, dry eye was found to be more 
common among glaucoma respondents than nonglaucoma controls 
(16.5% vs 5.6%, P<0.0001), and there was a nonsignificant trend for 
glaucoma patients with dry eye to report higher rates of intraocular 
pressure-lowering medications than those without dry eye (44.2% vs 
35.0%, P<0.076)(16). Interestingly, we found that the use of 2 or more 
antiglaucoma medications (OR=1.92) and duration of treatment 
greater than 5 years (OR=2.92) were significantly associated with 
dry eye. We believe that this association is explained by the fact that 
longer treatments with more drops per day have a higher load of 
preservatives delivered to the ocular surface. Martone et al.(17), in a 
comparative retrospective study using in vivo confocal microscopy, 
Table 1. Demographics of both populations
 
Glaucoma
N=175
Controls
N=175 P 
Age (years)   
Mean ± SD 66.6 ± 13.0 64.3 ± 13.8
Range 18 - 90 18 - 91 0.11*
Gender     
Male 076 43.4% 067 38.3%
Female 099 56.6% 108 61.7% 0.38**
Race     
Caucasian 154 88.0% 155 88.6%
Mixed 011 06.3% 009 05.1%
Asian 006 03.4% 005 02.9% 0.90***
African-american 004 02.8% 006 04.0%  
SD= standard deviation; *= ANOVA; **= Chi Square test; ***= Fisher Exact test.
Table 2. Characteristics of the glaucoma population
N=175 %
Type of glaucoma
POAG
PACG
Pigmentary glaucoma
144
027
004
82.3
15.4
02.2
Number of antiglaucoma medications
1
2
3
4
096
058
017
004
54.9
33.1
09.7
02.3
Type of antiglaucoma medication
Betablocker
Prostaglandin analogue
Carbonic anhydrase inhibitor
Alpha agonist
Fixed combination BB/PG
Fixed combination BB/CAI
Fixed combination BB/AA
040
080
025
018
031
048
008
22.9
45.7
14.3
10.3
17.7
27.4
04.6
POAG= primary open-angle glaucoma; PACG= primary angle-closure glaucoma; BB= 
betablocker; CAI= carbonic anhydrase inhibitor; PG= prostaglandin; AA= alpha agonist.
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found lower density of superficial epithelial cells, higher density of 
basal epithelial cells, higher stromal keratocyte activation, less sub-
ba sal nerves and higher tortuosity on glaucomatous patients with 
chronic treatment. These significant ocular surface alterations were 
associated with clinical tests. One of the limitations of our study 
is that the data analyzed did not include specific tests for dry eye. 
However, even if this was a prospective study, defining dry eye (also 
recently termed dysfunctional tear syndrome)(18) is still controversial. 
For example, some clinicians consider the diagnosis of dry eye only 
if decreased tear secretion or stability and ocular surface staining is 
documented, but there is a significant trend to consider the diagnosis 
based on symptoms as an early indicator of ocular surface disea-
se(6,13,19,20). Also, there is no single objective method which is accepted 
to effectively detect the presence of dry eye.
Although a clinical diagnosis of dry eye was not possible in our 
series, it is likely that the majority of patients using artificial tears 
present with some degree of tear dysfunction, considering that the 
main indication of artificial tears is to relieve symptoms related to 
dry eye. Artificial tears administration in glaucomatous patients with 
dry eye also seems to improve significantly reliability parameters and 
visual field indices(21). However, a study including a complete clinical 
examination of the ocular surface, including tear break-up time, 
ocular surface staining, Schirmer test, and eventually tear osmolarity 
is warranted. 
We also identified female gender, number of antiglaucoma me -
dications and duration of glaucoma treatment as risk factors for the 
need of artificial tears. Female gender has been listed as a risk factor 
for dry eye(13,20). Other studies have also reported number of antiglau-
coma medications as a risk factor for dry eye. Fechtner et al.(1), obser-
ved that the mean OSDI score significantly increased from 12.9 when 
one antiglaucoma medication was used to 19.4 when three or more 
medications were used (p=0.0001). Other authors(22) investigated the 
occurrence of dry eye syndrome (defined as presence of punctuate 
keratitis or decreased tear break-up time) in 61 glaucoma patients 
divided according to the number of glaucoma drops instilled per 
day (1, 2, or 3). The prevalence of dry eye was 40% in patients using 
3 drops/day, 39% in patients using 2 drops/day, and 11% in patients 
using one drop/day. Furthermore, OSDI questionnaires revealed that 
15% of those using 3 drops/day and 8.7% of those using 2 drops/day 
showed severe OSD. Finally, Pisella et al.(4), observed that the prevalen-
ce of ocular symptoms and signs related to dry eye were dose depen-
dent, increasing with the number of preserved antiglaucoma drops.
Although there is some evidence that glaucoma per se may be 
associated with decreased basal tear turnover(23), most of the studies 
blame the development of dry eye on the chronic use of antiglau-
coma medications, especially due to the presence of preservatives. 
It is conceivable that the effects of toxic preservatives on the ocular 
surface are cumulative, which explains why duration of treatment >5 
years was also a risk factor for the use of artificial tears in our series. 
The most frequently used preservative, BAK, is a quaternary ammo-
nium that causes tear film instability, loss of goblet cells, conjunctival 
metaplasia and apoptosis, and disruption of the corneal epithelial 
barrier, which leads to greater penetration of the drug in the anterior 
chamber3. Several studies have compared ocular surface symptoms 
and signs in patients using preserved vs. non-preserved eyedrops 
and all of them indicate that the use of preservative-free eye drops is 
associated with reduced ocular side effects(24,25).
Interestingly, some of our patients were using artificial tears con-
taining BAK as a preservative, which would theoretically worsen the 
ocular surface condition. It is important to emphasize that patients 
with OSD secondary to the chronic use of antiglaucoma medications 
should be preferably treated with preservative-free artificial tears. 
The use of plugs to decrease tear flow should be used with caution 
in these patients, since there is a possibility of increasing the contact 
between the preservative and the ocular surface.
CONCLUSION
Our study demonstrates that female gender and long-term treat -
ment of glaucoma with two or more medications may increase the 
need for artificial tears. The development of preservative-free anti-
glaucoma medications or medications with less toxic preservatives(26) 
is likely to benefit patients, reducing ocular surface changes(17) and 
possibly improving their quality of life.
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